WO2003063760A3 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases - Google Patents

Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases Download PDF

Info

Publication number
WO2003063760A3
WO2003063760A3 PCT/IL2003/000079 IL0300079W WO03063760A3 WO 2003063760 A3 WO2003063760 A3 WO 2003063760A3 IL 0300079 W IL0300079 W IL 0300079W WO 03063760 A3 WO03063760 A3 WO 03063760A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
diagnosing
methods
associated diseases
antibodies directed
Prior art date
Application number
PCT/IL2003/000079
Other languages
French (fr)
Other versions
WO2003063760A2 (en
Inventor
Ehud Gazit
Original Assignee
Univ Tel Aviv Future Tech Dev
Ehud Gazit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/235,852 external-priority patent/US20040052928A1/en
Application filed by Univ Tel Aviv Future Tech Dev, Ehud Gazit filed Critical Univ Tel Aviv Future Tech Dev
Priority to AU2003207973A priority Critical patent/AU2003207973A1/en
Priority to JP2003563456A priority patent/JP2006506942A/en
Priority to EP03704977A priority patent/EP1534310A4/en
Priority to KR10-2004-7011868A priority patent/KR20040081165A/en
Priority to CA2473987A priority patent/CA2473987C/en
Publication of WO2003063760A2 publication Critical patent/WO2003063760A2/en
Priority to IL163285A priority patent/IL163285A/en
Priority to AU2004203461A priority patent/AU2004203461B2/en
Priority to US10/901,243 priority patent/US20050020809A1/en
Publication of WO2003063760A3 publication Critical patent/WO2003063760A3/en
Priority to US11/471,657 priority patent/US7781396B2/en
Priority to US12/458,163 priority patent/US8012929B2/en
Priority to US12/654,461 priority patent/US8697634B2/en
Priority to US13/975,414 priority patent/US8993510B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Abstract

A peptide comprising at least 3 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions and kits including same, and methods using same for diagnosing and treating amyloid associated diseases.
PCT/IL2003/000079 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases WO2003063760A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2003207973A AU2003207973A1 (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
JP2003563456A JP2006506942A (en) 2002-01-31 2003-01-30 Peptides for diagnosing and treating amyloid-related diseases, antibodies thereto, and methods of use thereof
EP03704977A EP1534310A4 (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
KR10-2004-7011868A KR20040081165A (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
CA2473987A CA2473987C (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US10/901,243 US20050020809A1 (en) 2002-01-31 2004-07-29 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
AU2004203461A AU2004203461B2 (en) 2002-01-31 2004-07-29 Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
IL163285A IL163285A (en) 2002-01-31 2004-07-29 Peptides, antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US11/471,657 US7781396B2 (en) 2002-01-31 2006-06-21 Peptides directed for diagnosis and treatment of amyloid-associated disease
US12/458,163 US8012929B2 (en) 2002-01-31 2009-07-02 Peptides directed for diagnosis and treatment of amyloid-associated diseases
US12/654,461 US8697634B2 (en) 2002-01-31 2009-12-22 Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US13/975,414 US8993510B2 (en) 2002-01-31 2013-08-26 Peptides and methods using same for diagnosis and treatment of amyloid-associated disease

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35257802P 2002-01-31 2002-01-31
US60/352,578 2002-01-31
US39226602P 2002-07-01 2002-07-01
US60/392,266 2002-07-01
US10/235,852 2002-09-06
US10/235,852 US20040052928A1 (en) 2002-09-06 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US43645302P 2002-12-27 2002-12-27
US60/436,453 2002-12-27

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/235,852 Continuation-In-Part US20040052928A1 (en) 2002-01-31 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US10/235,852 Continuation US20040052928A1 (en) 2002-01-31 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/901,243 Continuation-In-Part US20050020809A1 (en) 2002-01-31 2004-07-29 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

Publications (2)

Publication Number Publication Date
WO2003063760A2 WO2003063760A2 (en) 2003-08-07
WO2003063760A3 true WO2003063760A3 (en) 2005-02-10

Family

ID=27671045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000079 WO2003063760A2 (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

Country Status (6)

Country Link
EP (1) EP1534310A4 (en)
JP (1) JP2006506942A (en)
KR (1) KR20040081165A (en)
AU (1) AU2003207973A1 (en)
CA (1) CA2473987C (en)
WO (1) WO2003063760A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927689B2 (en) 2002-12-09 2015-01-06 Ramot At Tel-Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US9394628B2 (en) 2004-08-02 2016-07-19 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070021345A1 (en) 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
ATE426575T1 (en) 2003-01-07 2009-04-15 Univ Ramot PEPTIDE ANOSTRUCTURES CONTAINING FOREIGN MATERIAL AND METHOD FOR PRODUCING THE SAME
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
JP5190957B2 (en) * 2006-04-28 2013-04-24 国立大学法人 鹿児島大学 Amyloid β fibrosis inhibiting peptide
CN101668525A (en) 2007-03-01 2010-03-10 前体生物药物股份公司 New use of glutaminyl cyclase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
JP5934645B2 (en) 2009-09-11 2016-06-15 プロビオドルグ エージー Heterocyclic derivatives as glutaminyl cyclase inhibitors
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
BR112013010549A2 (en) * 2010-10-29 2017-10-24 Merz Pharma Gmbh & Co Kgaa indole derivatives and process for their preparation
CA2817830A1 (en) 2010-11-15 2012-05-24 Ramot At Tel Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
MX365387B (en) 2012-09-12 2019-05-31 Neurimmune Holding Ag Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof.
KR101956302B1 (en) * 2016-11-30 2019-03-11 연세대학교 산학협력단 intracellular pH-responsive fusion peptide, phamaceutical composition for treatment of protein aggregation and misfolding related diseases
WO2019033099A1 (en) 2017-08-11 2019-02-14 University Of Kentucky Research Foundation Anti-neurodegenerative therapeutic, method of manufacture, and use
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6344895A (en) * 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd Anti-amyloid a protein monoclonal antibody
JPH09500140A (en) * 1993-07-19 1997-01-07 レゾリューション・ファーマスーティカルズ・インコーポレーテッド Hydrazino-type radionuclide chelating agent having N configuration 3 S configuration
JP2001504334A (en) * 1996-11-06 2001-04-03 アメリカ合衆国 Protease-activatable Pseudomonas exotoxin A-like proprotein
JP2000193661A (en) * 1998-12-25 2000-07-14 Tokyo Rika Kikai Kk Inspecting method for dementia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ [online] 18 May 1999 (1999-05-18), XP002999474, Database accession no. (AAW93015) *
DATABASE PROTEIN [online] 31 March 1993 (1993-03-31), XP002999475, Database accession no. (S04016) *
GORMAN ET AL.: "Alzheimer beta-amyloid peptides: Structures of amyloid fibrils and alternate aggregation products", BIOPOLYMERS, vol. 60, no. 5, 2001, pages 381 - 394, XP002999465 *
See also references of EP1534310A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927689B2 (en) 2002-12-09 2015-01-06 Ramot At Tel-Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US9394628B2 (en) 2004-08-02 2016-07-19 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures

Also Published As

Publication number Publication date
CA2473987C (en) 2013-11-19
KR20040081165A (en) 2004-09-20
JP2006506942A (en) 2006-03-02
AU2003207973A1 (en) 2003-09-02
WO2003063760A2 (en) 2003-08-07
EP1534310A2 (en) 2005-06-01
CA2473987A1 (en) 2003-08-07
EP1534310A4 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
WO2003063760A3 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
WO2005000193A3 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
BR0010720A (en) Antigenic neisseria peptides
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
CA2143125A1 (en) Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
CY1109946T1 (en) MODIFIED Peptides And Their Use For Autoimmune Disease Therapy
CA2361987A1 (en) Goodpasture antigen binding protein
WO2004014937A3 (en) Thrombin peptide derivatives
WO2004005317A3 (en) Thrombin peptide derivative dimers
WO2003022868A3 (en) Metal binding proteins and associated methods
CA2319699A1 (en) Placental protein 13
WO2005116658A3 (en) Method for determining a tissue degradation process by detection of comp neoepitopes
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
WO2003082897A3 (en) Synthetic active peptide fragments
WO2001002429A3 (en) Angiopoietin-6 and uses thereof
WO2004113566A3 (en) Disease related protein network
WO2004111086A3 (en) Peptide analogues comprising at least one type of aminoacyl aza-$g(b)3 and the use thereof, in particular for therapy
CA2285700A1 (en) Renin-active substance
AU2003202489A1 (en) Screening method
WO2003070770A3 (en) Engineered human kunitz-type protease inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2473987

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003704977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1671/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 163285

Country of ref document: IL

Ref document number: 10901243

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003563456

Country of ref document: JP

Ref document number: 1020047011868

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003704977

Country of ref document: EP